Datapoint: FDA Approves Alvotech and Teva’s Stelara Biosimilar

The FDA last week approved Alvotech and Teva’s Stelara biosimilar Selarsdi (ustekinumab-aekn) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older. The drugmakers said they plan to launch the drug, the second FDA-approved Stelara biosimilar behind Amgen’s Wezlana, in early 2025. For the treatment of psoriasis, Stelara currently holds covered or better status for 73% of all insured lives under the medical benefit. The biologic brought Johnson and Johnson $10.86 billion in global sales in 2023.

SOURCE: MMIT Analytics, as of 4/19/24 and Evaluate Pharma

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 14

Datapoint: Sandoz Reaches Agreement With Amgen to Launch Prolia, Xgeva Biosimilars

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today